xav939 and Brain-Infarction

xav939 has been researched along with Brain-Infarction* in 1 studies

Other Studies

1 other study(ies) available for xav939 and Brain-Infarction

ArticleYear
XAV939, a small molecular inhibitor, provides neuroprotective effects on oligodentrocytes.
    Journal of neuroscience research, 2014, Volume: 92, Issue:10

    White matter tracts are composed of axons and myelinating oligodendrocytes. Oligodendrocytes are the myelinating cells in the central nervous system that allow formation of myelin and saltatory nerve conduction. Cerebral white matter is highly vulnerable to ischemic injury in adults and neonates. White matter injury in newborn brains results in cerebral palsy and cognitive disability. In this study, we found that XAV939, a small-molecular inhibitor that stimulated β-catenin degradation by stabilizing axin, protected against serum and glucose deprivation (SGD)-induced cell death in oligodentrocyte cell line OLN-93 cells in a concentration-dependent manner. We further showed that XAV939 reduced caspase-3 and caspase-8 levels and increased the expression of phosphorylated Akt in SGD-induced OLN-93 cells. Our data demonstrate that XAV939 protects against neonatal hypoxic/ischemic injury. In summary, our results demonstrate that XAV939 confers neuroprotection against SGD-induced injury in OLN-93 cells via its antiapoptotic activity and the loss of oligodendrocytes and neurons in neonatal hypoxic/ischemic injury.

    Topics: Animals; Animals, Newborn; Apoptosis; beta Catenin; Brain Infarction; Brain Ischemia; Caspases; Cell Line, Transformed; Cells, Cultured; Chromones; Disease Models, Animal; Enzyme Inhibitors; Heterocyclic Compounds, 3-Ring; Morpholines; Neurons; Neuroprotective Agents; Oligodendroglia; Rats; Rats, Sprague-Dawley; Serum; Time Factors

2014